GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Curiox Biosystems Co Ltd (XKRX:445680) » Definitions » Cash Flow from Financing

Curiox Biosystems Co (XKRX:445680) Cash Flow from Financing : ₩19,833 Mil (TTM As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Curiox Biosystems Co Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Sep. 2024, Curiox Biosystems Co paid ₩0 Mil more to buy back shares than it received from issuing new shares. It received ₩0 Mil from issuing more debt. It paid ₩0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received ₩0 Mil from paying cash dividends to shareholders. It received ₩20,068 Mil on other financial activities. In all, Curiox Biosystems Co earned ₩20,068 Mil on financial activities for the three months ended in Sep. 2024.


Curiox Biosystems Co Cash Flow from Financing Historical Data

The historical data trend for Curiox Biosystems Co's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curiox Biosystems Co Cash Flow from Financing Chart

Curiox Biosystems Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
45,613.06 97.51 16,998.73 -236.66 17,643.69

Curiox Biosystems Co Quarterly Data
Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only 17,823.16 -27.75 -91.70 -22.12 19,974.99

Curiox Biosystems Co Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Curiox Biosystems Co's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Curiox Biosystems Co's Cash from Financing for the quarter that ended in Sep. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩19,833 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Curiox Biosystems Co  (XKRX:445680) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Curiox Biosystems Co's issuance of stock for the three months ended in Sep. 2024 was ₩0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Curiox Biosystems Co's repurchase of stock for the three months ended in Sep. 2024 was ₩0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Curiox Biosystems Co's net issuance of debt for the three months ended in Sep. 2024 was ₩0 Mil. Curiox Biosystems Co received ₩0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Curiox Biosystems Co's net issuance of preferred for the three months ended in Sep. 2024 was ₩0 Mil. Curiox Biosystems Co paid ₩0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Curiox Biosystems Co's cash flow for dividends for the three months ended in Sep. 2024 was ₩0 Mil. Curiox Biosystems Co received ₩0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Curiox Biosystems Co's other financing for the three months ended in Sep. 2024 was ₩20,068 Mil. Curiox Biosystems Co received ₩20,068 Mil on other financial activities.


Curiox Biosystems Co Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Curiox Biosystems Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Curiox Biosystems Co Business Description

Traded in Other Exchanges
N/A
Address
Samsung Harrington IT Tower, 204-213, 202, 2nd Floor, 9 Gil 41 Digital-Ro, Geumchun-Gu, Seoul, KOR, 08511
Curiox Biosystems Co Ltd is Korean Based company which brings together decades of scientific and engineering expertise in surface chemistry and life science instrumentation with the goal of overcoming critical challenges that slow the pace of life science research. The company has introduced Laminar Wash technology, which automates cell processing and enables highly reproducible and high-throughput cell analysis. The company offers various products such as LAMINAR WASH AUTO 1000 SYSTEM, Curiox Laminar Wash HT2000 System and Laminar Wash MINI System.

Curiox Biosystems Co Headlines

No Headlines